1 ts with Alzheimer's disease and psychosis or agitated behavior.

2         Most patients required treatment for agitated behaviors.

3 al score (which measures the frequency of 29 agitated behaviors) from baseline to week 12 for brexpip

4 noradrenergic activity may contribute to the agitated behaviors or cognitive deficits of patients wit

5                                          The Agitated Behavior Scale and other agitation measures wer

6                                     The mean Agitated Behavior Scale score for the nicotine replaceme

7                                          The Agitated Behavior Scale was used to measure the level of

8 titrate sedative medications and to evaluate agitated behavior, yet existing sedation scales have lim